Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T2IA
|
|||
| Former ID |
DAP000298
|
|||
| Drug Name |
Dapiprazole
|
|||
| Synonyms |
Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Approved | [1] | |
| Therapeutic Class |
Ophthalmologicals
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H27N5
|
|||
| Canonical SMILES |
CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
|
|||
| InChI |
1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
|
|||
| InChIKey |
RFWZESUMWJKKRN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 72822-12-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6823468, 10047683, 14801660, 36077438, 46508859, 50057655, 56394877, 57352743, 76691712, 85209404, 96024473, 111634408, 124963552, 126665781, 129123536, 134337610, 135012447, 137004989, 137939947, 143188853, 160963646, 164788310, 178103730, 179151036, 184533547, 184545929, 198943087, 223679991, 223702357, 226517331, 241132118, 241382806, 251916859, 251918098, 252347834, 252425541
|
|||
| ChEBI ID |
CHEBI:51066
|
|||
| SuperDrug ATC ID |
S01EX02
|
|||
| SuperDrug CAS ID |
cas=072822129
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.